Glenmark Pharma to Launch Ropivacaine Hydrochloride Injection in the US Market

Mumbai, October 23, 2025 – Glenmark Pharmaceuticals Limited (NSE: GLENMARK | BSE: 532296) has announced that its US-based subsidiary, Glenmark Pharmaceuticals Inc., intends to introduce Ropivacaine Hydrochloride Injection USP in the U.S. market this November. The injection will be available in three strengths: 40 mg/20 mL (2 mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL), each in single-dose vials.

Ropivacaine Hydrochloride Injection is bioequivalent and therapeutically equivalent to Fresenius Kabi USA, LLC’s Naropin Injection. Based on IQVIA data, for the 12 months ending August 2025, Naropin net sales in these dosage forms were approximately USD 20.9 million.

Details of Launch

Glenmark Pharmaceuticals Limited is set to introduce Ropivacaine Hydrochloride Injection USP in the U.S. market. The injection will be available in three strengths: 40 mg/20 mL (2 mg/mL), 150 mg/30 mL (5 mg/mL), and 200 mg/20 mL (10 mg/mL). This is the generic equivalent of Naropin® Injection, originally marketed by Fresenius Kabi USA, LLC.

According to IQVIA data, the U.S. market for Ropivacaine Hydrochloride Injection for the 12 months ending August 2025 is estimated at around USD 20.9 million. Glenmark plans to launch the product in November 2025, further strengthening its presence in the U.S. generics market.

Management Commentary

Marc Kikuchi, President & Business Head, North America, commented that the introduction of Ropivacaine Hydrochloride Injection marks “another important addition to Glenmark’s expanding injectable portfolio and reinforces the company’s dedication to bringing quality and affordable alternatives to patients in need”.

Share Price Update

As of 2:41 PM on 23 October 2025, Glenmark Pharmaceuticals Ltd share price was ₹1,863, up 0.42%. The stock opened at ₹1,869.00, reaching an intraday high of ₹1,879.20 and a low of ₹1,849.00. The company has a market capitalisation of ₹52,590 crore and a price-to-earnings (P/E) ratio of 69.77. It offers a dividend yield of 0.20%, with a quarterly dividend payout of ₹0.93 per share. Over the past 52 weeks, Glenmark’s shares have traded between ₹1,275.50 and ₹2,284.80.

Glenmark Pharmaceuticals ranks among the Top 100 biopharmaceutical companies by global sales and is listed among the Top 50 generics and biosimilar firms by Generics Bulletin. Glenmark’s greenhouse gas reduction targets have been approved by the Science Based Target initiative (SBTi), making it the second Indian pharmaceutical company to achieve this distinction. The launch further strengthens Glenmark’s presence in the North American market, underscoring its strategy to broaden its injectable product offerings globally.

REF: https://nsearchives.nseindia.com/corporate/GLENMARK_23102025091428_October23_Signed.pdf

Disclaimer: At HDFC SKY, we take utmost care and due diligence in curating and presenting news and market-related content. However, inadvertent errors or omissions may occasionally occur.

If you have any concerns, questions, or wish to point out any discrepancies in our content, please feel free to write to us at content@hdfcsec.com.

Please note that the information shared is intended solely for informational purposes and does not make any investment recommendations